The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee, and Board of Directors

October 21, 2020

Washington, DC

The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming year. The committee and board are subject to an annual re-election or rotation process, with nominations and approval by the ARM membership and current Board.


ARM and NAMCP Publish Recommendations to Increase Patient Access in Joint Study, “Roadmap for Navigating the Provider Side of Cell and Gene Therapy (CGT) Patient Access in US Managed Care.”

October 12, 2020

Washington, DC


The Alliance for Regenerative Medicine Applauds the Award of the Nobel Prize to CRISPR Pioneers

October 7, 2020

Washington, DC


The Alliance for Regenerative Medicine Applauds New Rule From the Centers for Medicare & Medicaid Services Promoting Access to Innovative Therapies

September 2, 2020

Washington, DC

The Alliance for Regenerative Medicine (ARM) applauds the Centers for Medicare and Medicaid Services’ (CMS) decision to finalize a new diagnosis-related group (DRG) for chimeric antigen receptor T cell (CAR-T) therapies in their FY21 Inpatient Prospective Payment System (IPPS) rule. This is a crucial step forward for patient access to life-changing therapies, and the result of multi-year collaboration among ARM, its members, regulators, and a diverse group of other stakeholders.